Safety and efficacy of pregabalin in adolescents with fibromyalgia

Primary tabs

SCIENCE
Safety and efficacy of pregabalin in adolescents with fibromyalgia
Key Take-Away: 

It has been already known that fibromyalgia in adolescents is related with significant impairment in physical functioning, lower perceived health status and higher healthcare utilization in contrast to age-matched healthy peers. Thus, this study was conducted to determine the efficacy of pregabalin in adolescents.

Fibromyalgia (FM) is a common pain condition characterized by widespread musculoskeletal pain and tenderness.

ABSTRACT: 
Background: 

Fibromyalgia (FM) is a common pain condition characterized by widespread musculoskeletal pain and tenderness.

Pregabalin is an approved treatment for adults in the United States, but there are no approved treatments for adolescents with FM.

Methods: 

This was a 15-week, randomized, double-blind, placebo-controlled study and 6-month open-label safety trial of flexible-dose pregabalin (75-450 mg/day) for the treatment of adolescents (12-17 years) with FM.

Primary outcome was change in mean pain score at endpoint (scored from 0-10, with 24-h recall). Secondary outcomes included global assessments and measures of pain, sleep, and FM impact.

Results: 

A total of 107 subjects were randomized to treatment (54 pregabalin, 53 placebo) and 80 completed the study (44 pregabalin, 36 placebo). Improvement in mean pain score at endpoint with pregabalin versus placebo was not statistically significant, treatment difference (95 % CI), -0.66 (-1.51, 0.18), P = 0.121.

There were significant improvements with pregabalin versus placebo in secondary outcomes of change in pain score by week (P < 0.05 for 10 of 15 weeks); change in pain score at week 15 (1-week recall), treatment difference (95 % CI), -0.87 (-1.68, -0.05), P = 0.037; and patient global impression of change, 53.1 % versus 29.5 % very much or much improved (P = 0.013). Trends toward improvement with pregabalin in other secondary outcomes measuring pain, sleep, and FM impact were not significant. Safety was consistent with the known profile of pregabalin in adults with FM.

 

Conclusion: 

Pregabalin did not significantly improve the mean pain score in adolescents with FM.

There were significant improvements in secondary outcomes measuring pain and impression of change.

 

ProHealth
Log in or register to post comments